TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18652266

Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (self-etching adhesive)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (self-etching adhesive)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: One Step (etch-and-rinse bonding agent)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 37% H3PO4 etching for 15 s
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 37% H3PO4 etching for 15 s and 5% NaOCl aq application for 2 min
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no specific adhesive mentioned)
Number of subjects: 180
Study: 16707519

Group type: EXPERIMENTAL
Intervention: Aphakic and pseudophakic patients after congenital cataract surgery
Number of subjects: 43

Group type: COMPARATOR
Intervention: Healthy age and sex matched controls
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Aphakic eyes with IOL implanted at congenital cataract surgery
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Aphakic eyes with secondary IOL implantation
Number of subjects: 43
Study: 12886826

Group type: EXPERIMENTAL
Intervention: CLD i.v., 300 mg/2 weeks and oral calcium carbonate (500 mg x 2/day) and vitamin D3 (400 IU x 2/day)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CLD i.m., 100 mg/week and the same doses of calcium and vitamin D3 as group A
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group receiving only calcium and vitamin D3
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CLD i.v. (group A)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CLD i.v. (group A) and CLD i.m. (group B)
Number of subjects: 84
Study: 10845828

Group type: EXPERIMENTAL
Intervention: CsA monotherapy
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: CsA in a single daily dose
Number of subjects: 143
Study: 9366890

Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laser vaporization prostatectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: EuroQol
Number of subjects: 0

Group type: COMPARATOR
Intervention: SF-36
Number of subjects: 0

Group type: COMPARATOR
Intervention: American Urological Association symptom score
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bothersome index
Number of subjects: 0
Study: 8439201

Group type: COMPARATOR
Intervention: Whole blood (no filter)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Blood passed through a leucocyte filter
Number of subjects: 57
Study: 3818144

Group type: EXPERIMENTAL
Intervention: Pirenzepin (20 mg intravenous injection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31357402

Group type: EXPERIMENTAL
Intervention: Low-salt bread (0.3 g salt/100 g) as part of a reduced-salt diet
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual-salt dietary period
Number of subjects: 97
Study: 29485064

Group type: EXPERIMENTAL
Intervention: 56 Gy (16 fractions of 3.5 Gy; arm A)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 67 Gy (25 fractions of 2.68 Gy; arm B)
Number of subjects: 160
Study: 27021174

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 60
Study: 25139150

Group type: EXPERIMENTAL
Intervention: Naftopidil 50 mg/day
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Naftopidil 50 mg/day plus Celecoxib 200 mg
Number of subjects: 103

Group type: COMPARATOR
Intervention: Celecoxib 200 mg
Number of subjects: 103
Study: 21858589

Group type: EXPERIMENTAL
Intervention: Late course accelerated hyperfraction (LCAF) three-dimensional conformal radiotherapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Conventional fraction (CF) three-dimensional conformal radiotherapy
Number of subjects: 98
Study: 22163454

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic circulator
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (without the circulator)
Number of subjects: 16
Study: 17631866

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX: 30, 50, or 70 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Mixed amphetamine salts extended-release (MAS XR: 10, 20, or 30 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 15740944

Group type: EXPERIMENTAL
Intervention: Low-pressure suction applied to underwater seal drains postoperatively
Number of subjects: 239

Group type: COMPARATOR
Intervention: No suction applied to underwater seal drains postoperatively
Number of subjects: 239
Study: 12045762

Group type: EXPERIMENTAL
Intervention: Fränkel Functional Regulator‐II (FR‐II) treatment for 18 months
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not treated during the observation period)
Number of subjects: 56
Study: 10208142

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate, 100 mg by intramuscular injection once a week for 6 months
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo by intramuscular injection once a week for 6 months
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 8903607

Group type: EXPERIMENTAL
Intervention: Non-potassium-sparing diuretics
Number of subjects: 371

Group type: COMPARATOR
Intervention: Potassium-sparing diuretic therapy
Number of subjects: 371
Study: 2469097

Group type: EXPERIMENTAL
Intervention: Clonidine treatment
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31857335

Group type: EXPERIMENTAL
Intervention: Lowered tackle height setting (Championship Cup, 36 games)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard tackle height setting (Championship, 90 games)
Number of subjects: 126
Study: 31280434

Group type: EXPERIMENTAL
Intervention: Panitumumab (6 mg/kg) plus docetaxel (50 mg/m2) and cisplatin (50 mg/m2) every 2 weeks until disease progression, unacceptable toxicity, or patient withdrawal
Number of subjects: 44
Study: 29582422

Group type: EXPERIMENTAL
Intervention: 2.0 mg hyperbaric bupivacaine plus 15 μg fentanyl
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2.5 mg hyperbaric bupivacaine
Number of subjects: 30
Study: 26418629

Group type: EXPERIMENTAL
Intervention: Multimodal therapeutic program (added to standard care)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard care (Control Group)
Number of subjects: 49
Study: 26402815

Group type: EXPERIMENTAL
Intervention: Resistance Vibrating Exercise (RVE)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: RVE with high-protein supplement diet (NeX group)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Bed rest (Control group)
Number of subjects: 11
Study: 23934737

Group type: EXPERIMENTAL
Intervention: Mixture of ellagitannin-rich berries (specific dosage and duration not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 21035871

Group type: EXPERIMENTAL
Intervention: Contact technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Immersion technique
Number of subjects: 50
Study: 19060417

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/day for 1 week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day for 1 week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atorvastatin and fasudil (combination therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fasudil (selective Rho-kinase inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statins (atorvastatin, pitavastatin, pravastatin at 10 micromol/L)
Number of subjects: 0
Study: 17132351

Group type: EXPERIMENTAL
Intervention: Patient-held guideline with written explicit exhortation to challenge care
Number of subjects: 236

Group type: COMPARATOR
Intervention: Standard information
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Patient-held guideline
Number of subjects: 236
Study: 12923753

Group type: EXPERIMENTAL
Intervention: Guided imagery audiotapes (GI)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Music audiotapes (MU)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard care (C)
Number of subjects: 84
Study: 10895920

Group type: EXPERIMENTAL
Intervention: EMT-Bs evaluating wounds for repair
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: EMT-Bs evaluating forearm wounds
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: EMT-Bs identifying patients requiring tetanus prophylaxis
Number of subjects: 11

Group type: COMPARATOR
Intervention: Agreement between EMT-Bs and physicians on wound exclusion criteria
Number of subjects: 11
Study: 9065539

Group type: EXPERIMENTAL
Intervention: Respiratory chain enzyme activities in lymphocyte mitochondria from patients with Alzheimer's disease (AD)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Respiratory chain enzyme activities in lymphocyte mitochondria from healthy controls
Number of subjects: 63
Study: 8155929

Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Budesonide (800 micrograms daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3788644

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 558

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 558
Study: 31715262

Group type: EXPERIMENTAL
Intervention: Cold stimulus
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Heat stimulus
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pressure pain threshold (PPT) test stimulus
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sham conditioning stimuli
Number of subjects: 50
Study: 30473365

Group type: EXPERIMENTAL
Intervention: SEHER intervention delivered by lay counsellor (SM group)
Number of subjects: 14000

Group type: COMPARATOR
Intervention: SEHER intervention delivered by teacher (TSM group)
Number of subjects: 14000
Study: 27068361

Group type: EXPERIMENTAL
Intervention: Insulin analogues (detemir/aspart)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Human insulin (NPH/regular)
Number of subjects: 114
Study: 24597906

Group type: EXPERIMENTAL
Intervention: AVD optimization using impedance cardiography (ICG)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Factory setting group (AVDfab)
Number of subjects: 37
Study: 21762160

Group type: EXPERIMENTAL
Intervention: Self-affirmation manipulation
Number of subjects: 220

Group type: COMPARATOR
Intervention: Equivalently active control task
Number of subjects: 220
Study: 21105622

Group type: EXPERIMENTAL
Intervention: Heparin (75 units/kg intravenously) before clamping of the artery
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 48
Study: 18997913

Group type: EXPERIMENTAL
Intervention: SRP + insertion of doxycycline gel (SRP+DH)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SRP + insertion of chlorhexidine gel (SRP+CHX)
Number of subjects: 30

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 30
Study: 17116095

Group type: EXPERIMENTAL
Intervention: HPC (Headache and Pain Clinic)
Number of subjects: 181

Group type: COMPARATOR
Intervention: GP patients
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: HPC patients
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 181
Study: 12667121

Group type: COMPARATOR
Intervention: Warfarin alone (INR of 2.8 IU)
Number of subjects: 3620

Group type: COMPARATOR
Intervention: Combination of aspirin (75 mg/day) and warfarin (INR of 2.2 IU)
Number of subjects: 3620

Group type: EXPERIMENTAL
Intervention: Aspirin alone (160 mg/day)
Number of subjects: 3620

Group type: EXPERIMENTAL
Intervention: Warfarin alone
Number of subjects: 3620

Group type: EXPERIMENTAL
Intervention: Combination of aspirin and warfarin
Number of subjects: 3620

Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 3620
Study: 10941621

Group type: EXPERIMENTAL
Intervention: Sustained release theophylline (300 mg) with kinnow juice (300 ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sustained release theophylline (300 mg) with water (300 ml)
Number of subjects: 10
Study: 9322135

Group type: EXPERIMENTAL
Intervention: Neuroleptic withdrawal
Number of subjects: 36
Study: 7886617

Group type: EXPERIMENTAL
Intervention: High transfusion rates with subcutaneous desferrioxamine injections (Group A)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High transfusion without desferrioxamine (Group B)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Maintaining pretransfusion Hb levels between 6-7 g/dl (Group C)
Number of subjects: 18
Study: 3522813

Group type: EXPERIMENTAL
Intervention: sorbinil (100 mg daily for 4 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study: 31410338

Group type: EXPERIMENTAL
Intervention: Oral glutamine (10 gm two hours before radiotherapy, five days a week during the seven-week course)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Concurrent chemo-radiotherapy with oral glutamine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral glutamine
Number of subjects: 60
Study: 28380627

Group type: EXPERIMENTAL
Intervention: Cancer screening intervention (Fe en Acción)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Physical activity intervention (control)
Number of subjects: 436
Study: 26324049

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 7213

Group type: COMPARATOR
Intervention: Unfractionated Heparin
Number of subjects: 7213

Group type: EXPERIMENTAL
Intervention: Post-PCI Bivalirudin infusion
Number of subjects: 7213

Group type: COMPARATOR
Intervention: No post-PCI infusion
Number of subjects: 7213
Study: 23318995

Group type: EXPERIMENTAL
Intervention: Dietary inulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis + inulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis + Tetraselmis chuii
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis + Phaeodactylum tricornutum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inulin + Bacillus subtilis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inulin + Phaeodactylum tricornutum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All experimental diets containing Bacillus subtilis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All assayed diets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (not specified)
Number of subjects: 0
Study: 21737072

Group type: EXPERIMENTAL
Intervention: Frozen-thawed embryo transfer (FET)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Fresh embryo transfer (ET)
Number of subjects: 103
Study: 19659622

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 110
Study: 16773434

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 1176

Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 1176
Study: 15309879

Group type: EXPERIMENTAL
Intervention: Eradication of H. pylori
Number of subjects: 20

Group type: COMPARATOR
Intervention: No eradication of H. pylori
Number of subjects: 20
Study: 11116284

Group type: EXPERIMENTAL
Intervention: LJP-394, 100 mg intravenously weekly
Number of subjects: 0
Study: 9150290

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8121962

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 0
Study: 3501751

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ofloxacin 100mg single dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitrofurantoin
Number of subjects: 0
Study: 30354782

Group type: EXPERIMENTAL
Intervention: Intravascular Vascular Closure Device (VCD)
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Extravascular Vascular Closure Device (VCD)
Number of subjects: 1395

Group type: COMPARATOR
Intervention: Manual Compression (MC)
Number of subjects: 1395
Study: 26617051

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 437
Study: 25458454

Group type: EXPERIMENTAL
Intervention: HES 130/0.4 coloading (GroupV)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline solution coloading (GroupC)
Number of subjects: 120
Study: 22374637

Group type: EXPERIMENTAL
Intervention: Baseline cognitive function measured by Digit Symbol Substitution Test (DSST)
Number of subjects: 2956

Group type: EXPERIMENTAL
Intervention: Cognitive decline over 20 months
Number of subjects: 2956

Group type: COMPARATOR
Intervention: Randomization to intensive glycemic strategy
Number of subjects: 2956

Group type: COMPARATOR
Intervention: Randomization to standard glycemic strategy
Number of subjects: 2956
Study: 20462055

Group type: EXPERIMENTAL
Intervention: Modified Shegan Mahuang Decoction (SGMH), one dose per day for 4 weeks
Number of subjects: 154

Group type: COMPARATOR
Intervention: Montelukast, once a day for 4 weeks (4 mg for ages 2-5, 5 mg for ages 6-14)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Healthy children (control group for cytokine levels)
Number of subjects: 154
Study: 17681803

Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study: 15557131

Group type: EXPERIMENTAL
Intervention: Hydrocortisone infusion
Number of subjects: 46
Study: 12426013

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg IV
Number of subjects: 324

Group type: COMPARATOR
Intervention: Meperidine 50 mg IV
Number of subjects: 324
Study: 10598706

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the globus pallidus internus (GPi)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the globus pallidus internus (GPi) with L-dopa
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) with L-dopa
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) at either site
Number of subjects: 10
Study: 8614043

Group type: EXPERIMENTAL
Intervention: 5-cm H2O PEEP
Number of subjects: 44

Group type: COMPARATOR
Intervention: 0-cm H2O PEEP (ZEEP)
Number of subjects: 44
Study: 1936074

Group type: EXPERIMENTAL
Intervention: Moxonidine tablets (treatment A)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravenous moxonidine solution (treatment B)
Number of subjects: 18
Study: 6152884

Group type: EXPERIMENTAL
Intervention: Continuation of beta-receptor blockade
Number of subjects: 43

Group type: COMPARATOR
Intervention: Withdrawal of beta-receptor blockade
Number of subjects: 43
Study: 30887470

Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SoC) chemotherapy
Number of subjects: 0
Study: 29695902

Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI 28.8 μg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI 14.4 μg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI 7.2 μg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI (all doses)
Number of subjects: 66
Study: 25943172

Group type: EXPERIMENTAL
Intervention: Topical bevacizumab 5 mg/mL
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Topical bevacizumab 10 mg/mL
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 25007694

Group type: EXPERIMENTAL
Intervention: Sniffing position
Number of subjects: 378

Group type: COMPARATOR
Intervention: Simple head extension
Number of subjects: 378
Study: 22344744

Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tandospirone (20 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Paroxetine (10 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 19865833

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (4 sessions)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Supportive-experiential group therapy (4 sessions)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Treatment as usual (Control group, n = 91)
Number of subjects: 174
Study: 16765100

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (4 sessions at 3-month intervals for 1 year)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Usual care (standard medical care)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 190

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 190
Study: 15517339

Group type: EXPERIMENTAL
Intervention: 17-day spaceflight
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (8 ambulatory men)
Number of subjects: 4
Study: 12209483

Group type: EXPERIMENTAL
Intervention: Video information (4 minutes, 20 seconds duration)
Number of subjects: 112

Group type: COMPARATOR
Intervention: No video information
Number of subjects: 112
Study: 10590432

Group type: EXPERIMENTAL
Intervention: Chorionic Villus Sampling (CVS) using transcervical biopsy forceps
Number of subjects: 1313

Group type: COMPARATOR
Intervention: Mid-trimester amniocentesis
Number of subjects: 1313
Study: 8624224

Group type: EXPERIMENTAL
Intervention: 0.76% sodium monofluorophosphate (MFP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.247% sodium fluoride (NaF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.247% sodium fluoride (NaF) plus 1.3% pyrophosphate and 1.5% polyvinylmethyl ether/maleic acid (PVM/MA) copolymer (NaF/PPi)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (non-fluoride dentifrice)
Number of subjects: 0
Study: 1850339

Group type: EXPERIMENTAL
Intervention: Fludrocortisone acetate (Florinef) for 3 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atropine (i.v. administration)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 15
Study: 6991446

Group type: EXPERIMENTAL
Intervention: 0.75 mg digoxin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2.5 mg digoxin over four days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18